| Course | HLTH 5063 Biology and Disease Risk in Human Health |
|---|---|
| Module | Module 3 |
| Paper type | Host susceptibility and immunity analysis |
| Length | 1,180 words, about 4 pages plus title and reference pages |
| Format | APA 7 student paper |
| School | American College of Education |
| Program | Master of Public Health |
| Updated | September 2026 |
Free sample paper for HLTH 5063 Module 3
Why Some People Never Clear the Virus and Some Vaccines Never Take: Host Susceptibility, Immunity and Genetics in Hepatitis B
Student Name
American College of Education
HLTH5063: Biology and Disease Risk in Human Health
Module 3 Assignment
Instructor Name
October 19, 2026
The Host Half of the Equation
The first two modules followed hepatitis B from the virus to liver cancer. This module turns to the person the virus infects. Exposure to the same virus produces very different outcomes: most healthy adults clear an acute infection within months, while most infants infected at birth carry it for life; some people with chronic infection live for decades without serious liver damage, while others develop cirrhosis or cancer; and some adults who receive a full vaccine series never develop protective antibody. Those differences arise largely from the host, through age, immune function, genetics and conditions such as diabetes. Understanding them explains who needs protection most and why prevention tools must be adapted to different groups.
Age and Immune Tolerance
Age at infection is the strongest host factor. Edmunds et al. (1993), pooling survey data, found that roughly nine in ten babies infected before six months of age went on to carry the virus, fell steeply through early childhood and reached about 0.1 by adulthood. The biological explanation lies in immune tolerance. The newborn immune system tends not to mount a vigorous attack against the virus, which spares the infant acute hepatitis but allows the virus to persist. Adults, by contrast, usually mount a strong cellular immune response that clears infected liver cells, sometimes at the cost of a symptomatic acute illness. The same immune restraint that protects a newborn from a violent hepatitis is what lets the virus stay for a lifetime.
Immune Response and Liver Damage
In chronic infection, the virus itself does relatively little direct harm to liver cells; damage comes mainly from the host's ongoing immune attack on infected cells. That is why chronic hepatitis B passes through phases, with periods in which the virus replicates heavily but the liver shows little inflammation and periods in which the immune system becomes more active, liver enzymes rise and scarring accelerates. The pattern explains why two people with the same infection can have very different outcomes, and why clinicians monitor both viral levels and liver inflammation over time. It also explains why conditions that suppress immunity, such as chemotherapy, can allow a controlled infection to flare, and why people starting such treatment are tested for hepatitis B first.
Genetic Susceptibility
Genes shape how well the immune system recognizes the virus. In a genome-wide association study of Japanese patients with chronic hepatitis B and controls, validated in additional Japanese and Thai cohorts, Kamatani et al. (2009) found strong associations between chronic infection and variants in the HLA-DP region, part of the system that presents viral fragments to immune cells. Two variants associated with a lower likelihood of chronic infection had odds ratios of about 0.57 and 0.56, and specific combinations of HLA-DP alleles were associated with either higher risk, with odds ratios of 1.45 and 2.31, or lower risk.
These findings do not change public health practice directly; no one is screened for HLA type before vaccination. They do help explain why outcomes vary even among people infected at the same age, and they caution against interpreting differences in chronic infection between populations as purely environmental. For the county, the practical lesson remains that everyone in higher-risk communities should be tested and vaccinated regardless of individual genetic makeup.
Vaccine-Induced Immunity
Vaccination works by teaching the immune system to recognize the virus's surface antigen. National recommendations consider people who develop an antibody level of at least 10 milli-international units per milliliter after a complete series to be protected, and they note that antibody levels decline over time: about 16% of people vaccinated before age one still have that level 18 years later (Schillie et al., 2018). The decline does not mean protection has vanished, because immune memory allows a rapid response on exposure, which is why booster doses are not routinely recommended for healthy people vaccinated in infancy. It does mean that a single antibody test years after vaccination cannot always distinguish someone who never responded from someone whose antibody has faded, a practical problem for health care workers and others who need to confirm protection.
Adults Who Respond Poorly
Not everyone responds equally to vaccination. Response declines with age and is lower among people with diabetes, obesity, chronic kidney disease, immune suppression and among smokers. Newer vaccines address some of this gap. In a large randomized trial comparing a two-dose vaccine with a toll-like receptor 9 agonist adjuvant against a licensed three-dose vaccine, Jackson et al. (2018) found that among participants with type 2 diabetes, 90.0% of those receiving the two-dose vaccine were seroprotected at week 28 compared with 65.1% of those receiving the three-dose vaccine, and that the two-dose vaccine produced significantly higher seroprotection in the overall study population and every prespecified subgroup.
For the county, the finding has a practical side. Adults with diabetes are common among those who most need vaccination, and a vaccine that achieves protection in two doses over a month also improves the odds that busy adults will complete the series at all.
Pregnancy, Aging and Other Life Stages
Host susceptibility also changes across life stages, and those changes matter for policy. Pregnancy brings the highest-stakes moment in the virus's life cycle, because a mother with active infection can pass the virus to her newborn during delivery, when the infant's immune system is least able to clear it. That is why pregnant women are tested and why mothers with high viral loads may be offered antiviral treatment late in pregnancy to lower the amount of virus the baby is exposed to. At the other end of life, aging weakens the immune response to vaccination, so older adults are less likely to reach protective antibody levels after a standard series, and chronic infection that has been quiet for decades can become more damaging as liver scarring accumulates. Conditions acquired along the way, such as kidney failure requiring dialysis, HIV infection or treatment with drugs that suppress immunity, shift a person's susceptibility again, raising the risk of infection, reducing vaccine response or allowing a controlled infection to reactivate. A prevention program that treats adults as a single group will miss these differences; one organized around life stages can match testing, vaccination and monitoring to the moments when the host is most vulnerable.
Implications for Prevention
The host factors point to four priorities. Protect infants first, because their immune systems are least able to clear the virus. Test adults from high-burden communities, because many were infected in childhood and carry the virus silently regardless of genetic makeup. For people found to have chronic infection, provide ongoing monitoring, since immune activity and liver damage change over time, and test for hepatitis B before any immunosuppressive treatment. And for adults being vaccinated, especially those who are older or have diabetes, choose vaccines and schedules that maximize response and consider checking antibody after vaccination where the risk of exposure is high. The next module examines how the biology described in this course has shaped public health law and policy.
References
Edmunds, W. J., Medley, G. F., Nokes, D. J., Hall, A. J., & Whittle, H. C. (1993). The influence of age on the development of the hepatitis B carrier state. Proceedings of the Royal Society of London. Series B: Biological Sciences, 253(1337), 197-201. https://doi.org/10.1098/rspb.1993.0102
Jackson, S., Lentino, J., Kopp, J., Murray, L., Ellison, W., Rhee, M., Shockey, G., Akella, L., Erby, K., Heyward, W. L., Janssen, R. S., & HBV-23 Study Group. (2018). Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine, 36(5), 668-674. https://doi.org/10.1016/j.vaccine.2017.12.038
Kamatani, Y., Wattanapokayakit, S., Ochi, H., Kawaguchi, T., Takahashi, A., Hosono, N., Kubo, M., Tsunoda, T., Kamatani, N., Kumada, H., Puseenam, A., Sura, T., Daigo, Y., Chayama, K., Chantratita, W., Nakamura, Y., & Matsuda, K. (2009). A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nature Genetics, 41(5), 591-595. https://doi.org/10.1038/ng.348
Schillie, S., Vellozzi, C., Reingold, A., Harris, A., Haber, P., Ward, J. W., & Nelson, N. P. (2018). Prevention of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recommendations and Reports, 67(1), 1-31. https://doi.org/10.15585/mmwr.rr6701a1
The HLTH 5063 Module 3 assignment instructions
In HLTH 5063 Module 3, the prompt usually turns from the agent to the host. Expect to explain why people exposed to the same disease or risk have different outcomes, drawing on factors such as age, immune function, genetics, nutrition and chronic conditions, and to connect those factors to prevention and control. Many versions ask specifically about immunity, including natural and vaccine-induced protection, and some ask about genetic susceptibility. Graders expect biological mechanisms explained clearly and supported with studies that report effect sizes. Stay with the disease you have been studying if the course builds on one topic, and look in Canvas for whether a particular host factor must be addressed.
How the HLTH 5063 Module 3 example is put together
The model opens by framing variation in outcomes as a host question. Age at infection is quantified from its source and explained through immune tolerance. The immune basis of liver damage is linked to disease phases, monitoring and flares during immunosuppression. A genome-wide association study is reported with effect sizes and a careful statement of what it does and does not change in practice. Vaccine immunity is defined by its antibody threshold, with waning and immune memory explained. A randomized trial quantifies poor vaccine response in adults with diabetes and how a newer vaccine narrows it. The paper closes with four prevention priorities.
Reading the HLTH 5063 Module 3 rubric
Host susceptibility rubrics generally reward accurate explanation of immune and genetic mechanisms, use of studies with effect sizes, attention to variation across groups and application to prevention. Graders check that concepts such as immune tolerance, seroprotection and immune memory are explained correctly. Genetic findings earn credit when their limits for practice are acknowledged. Papers score higher when host factors are linked to specific prevention decisions, such as vaccine choice. Clear explanation for readers without laboratory training is valued, since public health audiences include managers and community partners. Current sources and a tidy reference list in APA 7 style earn the remaining points, and a paper that links each host factor to a prevention step tends to score higher on application.
Common HLTH 5063 Module 3 mistakes, and how to avoid them
Host papers lose points when they describe the immune system in textbook detail without linking it to who gets sick. Another frequent error is overstating genetic findings, as though a gene determined an individual's fate. Students also confuse falling antibody with lost protection. Explain each mechanism in plain terms. Report odds ratios or protection rates. Say what each finding means for prevention. Keep genetics in proportion and avoid implying that genes decide an individual's fate; age at infection and immune status usually explain far more of the variation a health department sees. Influenza, HPV and measles can all be examined from the host's side; tell us which disease your course follows and what the rubric asks, and the Module 3 paper can be shaped to it.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official American College of Education document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.
More HLTH 5063 and Master of Public Health sample papers
- HLTH 5063 Module 1: Disease Biology and Transmission
- HLTH 5063 Module 2: Disease Risk Factor Analysis
- HLTH 5063 Module 4: Biology and Policy Analysis
- HLTH 5063 Module 5: Policy Recommendation
- HLTH 5023 Module 3: Public Health Ethics Analysis
- HLTH 5083 Module 3: Capstone Options Analysis
- HLTH 5023 Module 5: Policy Recommendation
- HCI 5073 Module 1: Surveillance System Assessment
HLTH 5063 Module 3 questions, answered
What does HLTH5063 Module 3 usually ask for?
In HLTH5063, the third module generally turns to the host side of disease: how age, immunity, genetics and other conditions shape who becomes sick, who clears infection and who responds to prevention. The disease is carried over from your own section.
Why do infants infected with hepatitis B usually become chronic carriers?
Their immune systems tend to tolerate the virus rather than attack it, which prevents acute illness but allows the infection to persist.
Does falling antibody after hepatitis B vaccination mean protection is lost?
Not necessarily. Immune memory can produce a rapid response on exposure, which is why routine boosters are not recommended for healthy people vaccinated in infancy.
Where can I find a free HLTH 5063 Module 3 sample paper?
This page has the complete Module 3 paper on host susceptibility in hepatitis B, covering age and immune tolerance, immune-mediated liver damage, HLA-DP genetics, vaccine immunity and adults who respond poorly.
Who responds less well to hepatitis B vaccine?
Older adults and people with diabetes, obesity, kidney disease, immune suppression or who smoke tend to have lower response rates, which newer vaccines can partly overcome.